NCT03127098 2024-08-06
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
NantCell, Inc.
Phase 1/2 Terminated
NantCell, Inc.
Turning Point Therapeutics, Inc.
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center